FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1965303921> ?p ?o ?g. }

• W1965303921 endingPage "162.e1" @default.
• W1965303921 startingPage "155" @default.
• W1965303921 abstract "Accelerated phase CML most frequently represents a progression state in CML. However, some patients present with AP features at the time of diagnosis. There is limited information on the outcome of these patients who received TKIs as initial therapy.We analyzed the outcome of 51 consecutive patients with CML who presented with features of AP at the time of diagnosis, including blasts ≥ 15% (n = 6), basophils ≥ 20% (n = 22), platelets < 100 × 10(9)/L (n = 3), cytogenetic clonal evolution (n = 17), or more than 1 feature (n = 3). Patients received initial therapy with imatinib (n = 30), dasatinib (n = 5), or nilotinib (n = 16).The rate of complete cytogenetic response for patients treated with imatinib was 80%, and with dasatinib or nilotinib was 90%. Major molecular response (MMR) (Breakpoint Cluster Region (BCR)-Abelson (ABL)/ABL ≤ 0.1%, International Scale [IS]) was achieved in 69% of patients including complete molecular response (BCR-ABL/ABL ≤ 0.0032% IS) in 49%. MMR rates for patients treated with imatinib were 63%, and with 2GTKIs, 76%. Overall survival at 36 months was 87% with imatinib and 95% with 2GTKIs.TKIs should be considered standard initial therapy for patients with AP at the time of diagnosis." @default.
• W1965303921 created "2016-06-24" @default.
• W1965303921 creator A5000750846 @default.
• W1965303921 creator A5002756413 @default.
• W1965303921 creator A5006104041 @default.
• W1965303921 creator A5007915014 @default.
• W1965303921 creator A5009316700 @default.
• W1965303921 creator A5015140142 @default.
• W1965303921 creator A5019337932 @default.
• W1965303921 creator A5020340537 @default.
• W1965303921 creator A5028845635 @default.
• W1965303921 creator A5029703058 @default.
• W1965303921 creator A5030500582 @default.
• W1965303921 creator A5048913229 @default.
• W1965303921 creator A5049385583 @default.
• W1965303921 creator A5055045706 @default.
• W1965303921 creator A5059138314 @default.
• W1965303921 creator A5061026876 @default.
• W1965303921 creator A5085521139 @default.
• W1965303921 creator A5090435894 @default.
• W1965303921 date "2014-04-01" @default.
• W1965303921 modified "2023-10-15" @default.
• W1965303921 title "Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase" @default.
• W1965303921 cites W1901923962 @default.
• W1965303921 cites W1964261631 @default.
• W1965303921 cites W1970012935 @default.
• W1965303921 cites W1978514731 @default.
• W1965303921 cites W1999749854 @default.
• W1965303921 cites W2021413430 @default.
• W1965303921 cites W2028959752 @default.
• W1965303921 cites W2034469570 @default.
• W1965303921 cites W2039978091 @default.
• W1965303921 cites W2049595057 @default.
• W1965303921 cites W2075193502 @default.
• W1965303921 cites W2092509861 @default.
• W1965303921 cites W2095846263 @default.
• W1965303921 cites W2095911292 @default.
• W1965303921 cites W2122293465 @default.
• W1965303921 cites W2136782994 @default.
• W1965303921 cites W2148743957 @default.
• W1965303921 cites W2160007211 @default.
• W1965303921 cites W2163773009 @default.
• W1965303921 cites W2164872817 @default.
• W1965303921 cites W2171722798 @default.
• W1965303921 cites W2261840157 @default.
• W1965303921 cites W2312804644 @default.
• W1965303921 doi "https://doi.org/10.1016/j.clml.2013.08.008" @default.
• W1965303921 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3959284" @default.
• W1965303921 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24332214" @default.
• W1965303921 hasPublicationYear "2014" @default.
• W1965303921 type Work @default.
• W1965303921 sameAs 1965303921 @default.
• W1965303921 citedByCount "46" @default.
• W1965303921 countsByYear W19653039212014 @default.
• W1965303921 countsByYear W19653039212015 @default.
• W1965303921 countsByYear W19653039212016 @default.
• W1965303921 countsByYear W19653039212017 @default.
• W1965303921 countsByYear W19653039212018 @default.
• W1965303921 countsByYear W19653039212019 @default.
• W1965303921 countsByYear W19653039212020 @default.
• W1965303921 countsByYear W19653039212021 @default.
• W1965303921 countsByYear W19653039212022 @default.
• W1965303921 countsByYear W19653039212023 @default.
• W1965303921 crossrefType "journal-article" @default.
• W1965303921 hasAuthorship W1965303921A5000750846 @default.
• W1965303921 hasAuthorship W1965303921A5002756413 @default.
• W1965303921 hasAuthorship W1965303921A5006104041 @default.
• W1965303921 hasAuthorship W1965303921A5007915014 @default.
• W1965303921 hasAuthorship W1965303921A5009316700 @default.
• W1965303921 hasAuthorship W1965303921A5015140142 @default.
• W1965303921 hasAuthorship W1965303921A5019337932 @default.
• W1965303921 hasAuthorship W1965303921A5020340537 @default.
• W1965303921 hasAuthorship W1965303921A5028845635 @default.
• W1965303921 hasAuthorship W1965303921A5029703058 @default.
• W1965303921 hasAuthorship W1965303921A5030500582 @default.
• W1965303921 hasAuthorship W1965303921A5048913229 @default.
• W1965303921 hasAuthorship W1965303921A5049385583 @default.
• W1965303921 hasAuthorship W1965303921A5055045706 @default.
• W1965303921 hasAuthorship W1965303921A5059138314 @default.
• W1965303921 hasAuthorship W1965303921A5061026876 @default.
• W1965303921 hasAuthorship W1965303921A5085521139 @default.
• W1965303921 hasAuthorship W1965303921A5090435894 @default.
• W1965303921 hasBestOaLocation W19653039212 @default.
• W1965303921 hasConcept C121608353 @default.
• W1965303921 hasConcept C126322002 @default.
• W1965303921 hasConcept C143998085 @default.
• W1965303921 hasConcept C170493617 @default.
• W1965303921 hasConcept C2777413986 @default.
• W1965303921 hasConcept C2777583451 @default.
• W1965303921 hasConcept C2778729363 @default.
• W1965303921 hasConcept C2778820342 @default.
• W1965303921 hasConcept C2779536868 @default.
• W1965303921 hasConcept C3019892230 @default.
• W1965303921 hasConcept C42362537 @default.
• W1965303921 hasConcept C71924100 @default.
• W1965303921 hasConcept C90924648 @default.
• W1965303921 hasConceptScore W1965303921C121608353 @default.
• W1965303921 hasConceptScore W1965303921C126322002 @default.

• next